Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study-Reference-Cited by-同舟云学术

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study

Published:2017-11-06 Issue:1 Volume:15 Page:
ISSN:1477-7819
Container-title:World Journal of Surgical Oncology
language:en
Short-container-title:World J Surg Onc

Author:

Yang Wenjing,Gao Yibo,Li Xuelian,Zhang Jing,Liu Tiejun,Feng Xiaoli,Pan Hao,Yang Xiaofan,Xie Shuanghua,Feng Xiaoshuang,Lv Zhangyan,Wang Yonggang,Chen Zhaoli,He Jie^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1186/s12957-017-1251-z.pdf

Reference28 articles.

1. Arribas J, Baselga J. Who will benefit from treatment against EGFR? Lancet Oncol. 2005;6(5):257–8.

2. Heinrich MC, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342–9.

3. Tamura K, et al. Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403). Br J Cancer. 2008;98(5):907–14.

4. Rosell R, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med. 2009;361(10):958–67.

5. Shepherd FA, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353(2):123–32.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real world treatment patterns, healthcare resource use and costs in patients with advanced or metastatic non-small cell lung cancer by EGFR mutation type;Journal of Medical Economics;2024-02-13

2. B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors;World Journal of Surgical Oncology;2022-05-20

3. Long Term Survival in Patients with Metastatic Adenocarcinoma of the Lung in the Era of Targeted Agents;Journal of Medical and Radiation Oncology;2021-12

4. Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets;OncoTargets and Therapy;2021-09

5. Postoperative adjuvant EGFR-TKIs for resected EGFR-mutant NSCLC—opportunities and obstacles;Annals of Translational Medicine;2021-04